Chapter 2 64 ◀ Figure S6. Association of TLS, LA and CD20 with clinical benefit. (A) Top: Example of a CD20-CD3 IHC double staining with the black square showing CD20+ B cells (in yellow) and CD3+ T cells (in purple) localizing in TLS. Bottom: Digital markup to quantify CD20positive areas. Colors indicate intensity of the staining. (B) CD20-positive area per mm2 in pretreatment samples with presence (n=46) and absence (n=40) of TLS and/or LA (referred as TLS+LA). Shown is the mean. (C) PD-1T TILs per mm2 inside and outside TLS+LA in resected samples (n=27) and of total tumor area for resected samples with no TLS+LA (n=5). Medians, interquartile ranges and minimum/maximum shown in boxplots, ****P<0.0001 by MannWhitney test. (D) TLS+LA per mm2 in pretreatment samples from patients with DC 12m (n=20) and PD (n=71). Shown is the mean, *P=0.02 by Mann-Whitney test. (E) TLS and (F) TLS+LA per mm2 in pretreatment samples from patients with DC 6m (n=27) and PD (n=64). Shown is the mean, *P=0.03, **P<0.01 by Mann-Whitney test. (G) The predictive value of PD1T TILs, TLS, TLS+LA and CD20-positive area per mm2 for DC 6m (n=91, note that this cohort is smaller due to the availability of FFPE material). Shown are AUCs with 95% CI interval.
RkJQdWJsaXNoZXIy MTk4NDMw